Irhythm Technologies ( (IRTC) ) has released its Q2 earnings. Here is a breakdown of the information Irhythm Technologies presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
iRhythm Technologies, Inc. is a digital healthcare company that specializes in developing solutions for detecting, predicting, and preventing diseases, primarily focusing on cardiac monitoring through wearable biosensors and data analytics.
In its second quarter of 2025, iRhythm Technologies reported a significant financial performance with a 26.1% increase in revenue compared to the same period in 2024, reaching $186.7 million. The company also improved its gross margin to 71.2%, reflecting a 130-basis point increase.
Key highlights from the quarter include record revenue driven by the core long-term continuous monitoring business, sustained demand for the Zio AT product, and contributions from international markets. Additionally, iRhythm announced a strategic partnership with Lucem Health to enhance early detection of cardiac arrhythmias using AI technology. The company also presented findings from two large-scale studies that emphasize the importance of early detection strategies in at-risk populations.
Despite reporting a net loss of $14.2 million, iRhythm reduced its loss compared to the previous year, driven by revenue growth and operational efficiencies. The company holds $545.5 million in unrestricted cash and marketable securities, positioning it well for future investments and growth.
Looking ahead, iRhythm has increased its fiscal year 2025 guidance for revenue and adjusted EBITDA, projecting revenues between $720 million and $730 million. The company remains focused on expanding its market presence and leveraging its AI capabilities to revolutionize cardiac care.